Blog Viewer

Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke

By Currents Editor posted 03-02-2020 10:13

  

Journal of the American Medical Association (02/20/20) doi: 10.1001/jama.2020.1511

Campbell, Bruce C. V.; Mitchell, Peter J.; Churilov, Leonid; et al.

While I.V. thrombolysis with tenecteplase is superior to alteplase in improving cerebral reperfusion in ischemic stroke patients, it was unknown if tenecteplase's performance is influenced by dose. To explore, researchers in Australia and New Zealand assembled a trial population of 300 adults with ischemic stroke caused by large vessel occlusion. Participants in the EXTEND-IA TNK study Part II were randomized by a ratio of 1:1 to receive either 0.40 mg/kg or 0.25 mg/kg of tenecteplase, administered as a bolus before endovascular thrombectomy. The primary endpoint was reperfusion of more than 50% of the involved ischemic territory before thrombectomy. The share of patients who satisfied this goal was 19.3% for both groups, signifying no additional benefit to giving patients a higher dose.

#LiteratureWatch

FURTHER READING
Yang P, Zhang Y, Zhang L, et al. Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke. N Engl J Med . 2020 May 21;382(21):1981-93. Reviewed by Wazim Mohamed, MD Read the article .*   *You will need to log in to US National Library of Medicine National Institutes ...
By Thomas D. Bernier, PharmD; and Michael Schontz, PharmD, BCPS, BCCCP Aneurysmal subarachnoid hemorrhage (aSAH) accounts for 5% of all strokes, and due to a multitude of complications, patients are at exceptional risk of mortality and morbidity. 1 The incidence of aSAH is geographically diverse ...
The Neurocritical Care Society (NCS) is proud to launch the September 2020 issue of Currents , featuring a compilation of content published on Currents throughout this extraordinary year.  This special annual issue reflects on how neurocritical care professionals have addressed COVID-19, while ...